<DOC>
	<DOCNO>NCT01036113</DOCNO>
	<brief_summary>This Phase 2 , multicenter , open-label , noncomparative study evaluate safety , efficacy single-agent EZN 2208 administer patient previously treat MBC . After discontinuation study treatment , patient receive care consider appropriate investigator . Patients continue follow disease progression , subsequent anticancer therapy , survival .</brief_summary>
	<brief_title>A Phase 2 Study EZN-2208 Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>EZN-2208 administer i.v . infusion weekly 3 week 4-week cycle . Study treatment continue evidence disease progression , unacceptable toxicity , withdrawal patient 's consent participation study . Approximately 160 patient previously treat MBC enrol study . Eighty patient two cohort evaluate follow : 1 . AT Cohort - Patients treat prior anthracycline taxane adjuvant metastatic therapy ; 2 prior chemotherapy regimens MBC 2 . ATX Cohort - Patients treat prior anthracycline , taxane , XelodaÂ® ( capecitabine ) adjuvant metastatic therapy ; 4 prior chemotherapy regimen MBC After discontinuation study treatment , patient receive care consider appropriate investigator . Patients continue follow disease progression , subsequent anticancer therapy , survival least 6 month enrollment last patient study</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm breast adenocarcinoma metastatic . Receptor status tumor must know . Disease progression immediate previous therapy , intolerable toxicity lead cessation immediate previous therapy Previous treatment MBC : AT Cohort : Prior AT require adjuvant metastatic therapy ; 2 prior chemotherapy regimens MBC . ATX Cohort : Prior ATX require adjuvant metastatic therapy ; 4 prior chemotherapy regimens MBC . For patient positive receptor status : Patients HER2+ MBC must receive prior trastuzumab . Patients ER+ MBC must receive prior hormone therapy . Measurable disease RECIST Version 1.1 Women 18 year old ECOG performance status 0 2 Adequate bone marrow , renal hepatic function Major surgery within 3 week study start Known suspect brain metastasis require intervention steroid and/or radiation therapy Prior chemotherapy , immunotherapy , noninvestigational agent , therapy use treat cancer within 3 week schedule administration EZN2208 History primary cancer within 5 year enrollment , unless 1 . Curatively resect nonmelanomatous skin cancer , 2 . Curatively resected cervical cancer Lack recovery Grade 1 reversible side effect relate administration investigational agent , chemotherapy , prior treatment cancer Current participation another clinical study investigational agent and/or use investigational drug ( include investigational use approve drug ) 30 day first administration EZN2208 Known chronic infectious disease , AIDS</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>EZN-2208 ( PEG-SN38 )</keyword>
</DOC>